Biotech News

Olema Oncology Announces Corporate Name Change

Olema Pharmaceuticals, Inc. (OLMA)Olema Pharmaceuticals, Inc.Company update

SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer

Related news

Olema Pharmaceuticals, Inc.

Endocrine-Driven Cancer Company Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer. Palazestrant Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast...

Recent company news

Stock data

Close
7.15 USD
Market cap
933.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States